Prosecution Insights
Last updated: April 19, 2026

Momenta Pharmaceuticals Inc.

12 pending office actions

Portfolio Summary

12
Total Pending OAs
5
Final Rejections
7
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18452346 FCRN ANTIBODIES AND METHODS OF USE THEREOF ROONEY, NORA MAUREEN 1641 Final Rejection Aug 18, 2023
18218996 Sialylated Glycoproteins HADDAD, MAHER M 1641 Non-Final OA Jul 06, 2023
18218535 Sialylated Glycoproteins FAUST, AMBER KATHLEEN 1643 Non-Final OA Jul 05, 2023
18217401 Sialylated Glycoproteins LEONARD, ARTHUR S 1631 Non-Final OA Jun 30, 2023
18258189 ANTIBODIES AGAINST INTEGRIN ALPHA 11 BETA 1 GUSTILO, ESTELLA M 1646 Non-Final OA Jun 16, 2023
18136803 Sialylated Glycoproteins D' AMBROSIO, THEA 1654 Final Rejection Apr 19, 2023
18022069 SIALYLATED GLYCOPROTEINS KIM, YUNSOO 1641 Non-Final OA Feb 17, 2023
18022061 HYPERSIALYLATED IMMUNOGLOBULIN BOWERS, ERIN M 1653 Non-Final OA Feb 17, 2023
17925999 HYPER-SIALYLATED IMMUNOGLOBULIN GAO, ASHLEY HARTMAN 1678 Final Rejection Nov 17, 2022
17909282 METHODS OF MAKING HYPER-SIALYLATED IMMUNOGLOBULIN RAGHU, GANAPATHIRAM 1652 Final Rejection Sep 02, 2022
17519811 FCRN ANTIBODIES AND METHODS OF USE THEREOF BENAVIDES, JENNIFER ANN 1675 Non-Final OA Nov 05, 2021
17260318 COMPOSITIONS OF FCRN ANTIBODIES AND METHODS OF USE THEREOF DONOGHUE, BRITTNEY ERIN 1675 Final Rejection Jan 14, 2021

Managing Momenta Pharmaceuticals Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month